In the contemporary research landscape of mental illness treatment,fear-related disorders such as post-traumatic stress disorder continue to pose significant challenges.Although exposure therapy remains a fundamental ...In the contemporary research landscape of mental illness treatment,fear-related disorders such as post-traumatic stress disorder continue to pose significant challenges.Although exposure therapy remains a fundamental component of treatment,its efficacy varies considerably among individuals.DNA methylation plays a pivotal role in the extinction of fear memories,providing a promising molecular mechanism that could enhance the success of exposure-based interventions.Extensive studies have consistently demonstrated a substantial association between DNA methylation and neuronal plasticity.While DNA methylation holds potential regulatory effects on the effectiveness of exposure therapy,the bidirectional regulatory relationship between it and neuronal activity necessitates addressing several challenges before its widespread clinical application for mental disorders.First,excessive DNA methylation may suppress neural function,and non-selective enhancement of methylation could be counterproductive.Furthermore,due to potential systemic side effects,the use of methylation-modulating agents might disrupt the physiological balance and functionality of other organs and systems.Despite the dynamic interplay between DNA methylation and neuronal activity offering novel insights into the treatment of mental disorders, the strict consideration of target specificity and an appropriate dosing window requirescautious implementation in clinical practice.展开更多
In this editorial,we critically evaluate the recent article by Niu et al,which ex-plores the potential of phospholipase D2(PLD2)as a biomarker for stratifying disease severity in acute pancreatitis(AP).AP is a clinica...In this editorial,we critically evaluate the recent article by Niu et al,which ex-plores the potential of phospholipase D2(PLD2)as a biomarker for stratifying disease severity in acute pancreatitis(AP).AP is a clinically heterogeneous inflam-matory condition that requires reliable biomarkers for early and accurate classi-fication of disease severity.PLD2,an essential regulator of neutrophil migration and inflammatory responses,has emerged as a promising candidate.Although current biomarkers such as C-reactive protein and procalcitonin provide general indications of inflammation,they lack specificity regarding the molecular mechanisms underlying AP progression.Recent studies,including the research conducted by Niu et al,suggest an inverse correlation between PLD2 expression and AP severity,offering both diagnostic insights and mechanistic understanding.This editorial critically evaluates the role of PLD2 as a biomarker in the broader context of AP research.Evidence indicates that decreased levels of PLD2 are associated with increased neutrophil chemotaxis and cytokine release,con-tributing to pancreatic and systemic inflammation.However,several challenges remain,including the need for large-scale validation and functional studies to establish causation,and standardization of measurement protocols.Additionally,further investigation into the temporal dynamics of PLD2 expression and its variability across diverse populations is warranted.Looking ahead,PLD2 holds the potential to revolutionize AP management by integrating molecular diagnostics with precision medicine.The utilization of large-scale multi-omics approaches and advancements in diagnostic platforms could position PLD2 as a fundamental biomarker for early diagnosis,prognosis,and potentially therapeutic targeting.While promising,it is crucial to conduct critical evaluations and rigorous validations of PLD2’s role to ensure its efficacy in improving patient outcomes.展开更多
基金Supported by the General Program of the Joint Fund Project Under the Liaoning Provincial Science and Technology Plan,No.2024-MSLH-104Research Project Plan of the Qingpu Branch of Zhongshan Hospital,No.QYT2023-02Research Topic of the Shanghai Qingpu District Health Commission,No.QWJ2024-10.
文摘In the contemporary research landscape of mental illness treatment,fear-related disorders such as post-traumatic stress disorder continue to pose significant challenges.Although exposure therapy remains a fundamental component of treatment,its efficacy varies considerably among individuals.DNA methylation plays a pivotal role in the extinction of fear memories,providing a promising molecular mechanism that could enhance the success of exposure-based interventions.Extensive studies have consistently demonstrated a substantial association between DNA methylation and neuronal plasticity.While DNA methylation holds potential regulatory effects on the effectiveness of exposure therapy,the bidirectional regulatory relationship between it and neuronal activity necessitates addressing several challenges before its widespread clinical application for mental disorders.First,excessive DNA methylation may suppress neural function,and non-selective enhancement of methylation could be counterproductive.Furthermore,due to potential systemic side effects,the use of methylation-modulating agents might disrupt the physiological balance and functionality of other organs and systems.Despite the dynamic interplay between DNA methylation and neuronal activity offering novel insights into the treatment of mental disorders, the strict consideration of target specificity and an appropriate dosing window requirescautious implementation in clinical practice.
基金Supported by National Natural Sciences Foundation of China,No.82301700Liaoning Province Natural Science Foundation Project,No.2024-MS-157+2 种基金Youth Talent Cultivation Fund Key Project of Dalian Medical UniversityScientific Research Projects from Wuhan Municipal Health Commission,No.WX23Z26Science and Technology of Liaoning Province,No.2023-MS-266.
文摘In this editorial,we critically evaluate the recent article by Niu et al,which ex-plores the potential of phospholipase D2(PLD2)as a biomarker for stratifying disease severity in acute pancreatitis(AP).AP is a clinically heterogeneous inflam-matory condition that requires reliable biomarkers for early and accurate classi-fication of disease severity.PLD2,an essential regulator of neutrophil migration and inflammatory responses,has emerged as a promising candidate.Although current biomarkers such as C-reactive protein and procalcitonin provide general indications of inflammation,they lack specificity regarding the molecular mechanisms underlying AP progression.Recent studies,including the research conducted by Niu et al,suggest an inverse correlation between PLD2 expression and AP severity,offering both diagnostic insights and mechanistic understanding.This editorial critically evaluates the role of PLD2 as a biomarker in the broader context of AP research.Evidence indicates that decreased levels of PLD2 are associated with increased neutrophil chemotaxis and cytokine release,con-tributing to pancreatic and systemic inflammation.However,several challenges remain,including the need for large-scale validation and functional studies to establish causation,and standardization of measurement protocols.Additionally,further investigation into the temporal dynamics of PLD2 expression and its variability across diverse populations is warranted.Looking ahead,PLD2 holds the potential to revolutionize AP management by integrating molecular diagnostics with precision medicine.The utilization of large-scale multi-omics approaches and advancements in diagnostic platforms could position PLD2 as a fundamental biomarker for early diagnosis,prognosis,and potentially therapeutic targeting.While promising,it is crucial to conduct critical evaluations and rigorous validations of PLD2’s role to ensure its efficacy in improving patient outcomes.
